Candidate biomarker analyses in gastric or gastro-esophageal junction carcinoma: REGARD trial of single-agent ramucirumab (RAM) vs. placebo (PL).
Year: 2015
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Charles S. Fuchs, Josep Tabernero, Jiri Tomasek, Ian Chau, Bohuslav Melichar, Howard Safran, Mustapha Ali Tehfe, Filip Dumitru, Eldar Topuzov, Luis Schlittler, Anghel Adrian Udrea, William Campbell, Stephen Brincat, Michael Emig, Symantha A. Melemed, Rebecca R. Hozak, David Ferry, William Caldwell, Jaffer A. Ajani
Institutions: Dana-Farber Cancer Institute, Vall d'Hebron Hospital Universitari, Masaryk University, Masaryk Memorial Cancer Institute, Royal Marsden Hospital, University Hospital Olomouc, Palacký University Olomouc, Brown University, Centre Hospitalier de l’Université de Montréal, Sir Paul Boffa Hospital, Eli Lilly (Germany), Eli Lilly (United States), The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2340021104